Author

P. Trojer

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:differential expression· 1 Approach:experimental assay· 1 Research Focus:gene regulatory network inference· 1 Organism:human· 1 Approach:statistical model· 1

Frequent Co-Authors

A. Gopalan· 1 shared D. Li· 1 shared E. Campeau· 1 shared E. Corey· 1 shared G. Bayshtok· 1 shared H. Nguyen· 1 shared I. Ostrovnaya· 1 shared J. Conner· 1 shared

Activity by Year

2024-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Gopalan

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

BET inhibitors as a therapeutic intervention in gastrointestinal gene signature-positive castration-resistant prostate cancer.

S. Shukla, D. Li, H. Nguyen, J. Conner, G. Bayshtok, W. H. Cho, M. Pachai, N. Teri, E. Campeau, S. Attwell, P. Trojer, I. Ostrovnaya, A. Gopalan, E. Corey, P. Chi, Y. Chen

This study identifies BET inhibitors as effective against GI transcriptome-positive CRPC by targeting HNF1A and HNF4G, improving outcomes in preclinical models.

bioRxiv · Mar 9, 2024 · PreprintCancer Biology